dapi staining s7113 Search Results


anti nf κb p65  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc anti nf κb p65
( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB <t>p65</t> and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) (Ser536) and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.
Anti Nf κb P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti nf κb p65/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
anti nf κb p65 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
anti phospho nf κb p65 ser536  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc anti phospho nf κb p65 ser536
( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB <t>p65</t> and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) <t>(Ser536)</t> and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.
Anti Phospho Nf κb P65 Ser536, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho nf κb p65 ser536/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
anti phospho nf κb p65 ser536 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

Image Search Results


( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB p65 and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) (Ser536) and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.

Journal: JCI Insight

Article Title: Inhibiting calpain 1 and 2 in cyclin G associated kinase–knockout mice mitigates podocyte injury

doi: 10.1172/jci.insight.142740

Figure Lengend Snippet: ( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB p65 and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) (Ser536) and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.

Article Snippet: Mouse anti-GAK antibody (Santa Cruz Biotechnology, catalog: sc-137066); rabbit anti-GAK antibody (Invitrogen, Thermo Fisher Scientific, catalog: PA5-15321); mouse anti–transducin-like enhancer of split 4 (TLE4) antibody (Santa Cruz Biotechnology, catalog: sc-365406); rabbit anti-IκBα (Santa Cruz Biotechnology, catalog: sc-371); rabbit anti–NF-κB p65 (Cell Signaling Technology, catalog: 8242); rabbit anti-GADD45B antibody (Abcam, catalog: ab105060); rabbit anti–phospho-NF-κB p65 (Ser536) (Cell Signaling Technology, catalog: 3033); rabbit anti-WT1 antibody (Abcam, catalog: ab89901); mouse anti-WT1 antibody (MilliporeSigma, catalog: 05-753); rabbit anti-CAPNS1 antibody (MilliporeSigma, catalog: HPA006872); guinea pig anti-nephrin antibody (Progen, catalog: GP-N2); mouse anti-talin1 antibody (Cancer Research Technology, clone: 97H6); rabbit anti–β-actin antibody (Cell Signaling Technology, catalog: 5174); Alexa Fluor 488–conjugated phalloidin (Invitrogen, Thermo Fisher Scientific, catalog: A12379); Alexa Fluor 594–conjugated phalloidin (Invitrogen, Thermo Fisher Scientific, catalog: A12381); Alexa Fluor 488–conjugated goat anti–mouse IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11001); Alexa Fluor 594–conjugated goat anti–rabbit IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11037); Alexa Fluor 594–conjugated goat anti–guinea pig IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11076); DAPI/antifade solution (MilliporeSigma, catalog: S7113); mouse anti–mouse IgG horseradish peroxidase–conjugated (HRP-conjugated) antibody (Rockland, catalog: 18-8817-31); and rabbit anti–mouse IgG HRP-conjugated antibody (MilliporeSigma, catalog: AP160P) were purchased commercially.

Techniques: Western Blot, Control, Wilms Tumor Assay, Immunofluorescence, Expressing, Staining, Isolation

( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB p65 and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) (Ser536) and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.

Journal: JCI Insight

Article Title: Inhibiting calpain 1 and 2 in cyclin G associated kinase–knockout mice mitigates podocyte injury

doi: 10.1172/jci.insight.142740

Figure Lengend Snippet: ( A ) Representative Western blot images from control, Capns1 -KO, Gak -KO, and Gak/CapnsS1 -DKO mouse primary podocytes immunoblotted with GADD45B and Wilms tumor 1 (WT1). ( B ) Quantification of A by densitometry. n = 6. * P < 0.05 . ( C ) Representative immunofluorescence image of Gak -KO mouse glomeruli demonstrates increased GADD45B expression (GADD45B in green and WT1 in red). Scale bar: 50 μm. ( D ) Representative immunofluorescence image of glomeruli from control and FSGS patient stained with GADD45B (green) and TLE4 (red). Scale bar: 10 μm. ( E ) Quantification of C . n = 5 mice; 20 glomeruli per mouse were evaluated. ( F ) Quantification of D . n = 3 patients; 16 glomeruli per group were evaluated. ( G ) Gak -KO mice podocytes show IκBα cleavage (upper panel) and talin1 cleavage (middle panel) as determined by Western blots; these cleavage events were reduced by the podocyte-specific loss of Capns1 . ( H ) ChIP assay using phospho-NF-κB p65 and primer sets for Gadd45b promoter in the primary podocytes of control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice. n = 7. ( I ) Representative Western blot images for phospho-NF-κB p65 (pNF-κB p65) (Ser536) and total NF-κB p65 (NF-κB p65) from primary podocytes in control, Capns1 -KO, Gak -KO, and Gak/Capns1 -DKO mice. ( J ) Quantification of the nuclear NF-κB p65 activities of primary podocytes isolated from control (green), Capns1 -KO (red), Gak -KO (blue), and Gak/Capns1 -DKO (black) mice at the age of P14. n = 6. * P < 0.05 vs. control mice; # P < 0.05 vs. Gak -KO mice. ( E , F , H , and J ). Statistically analyzed via a 1-way ANOVA with Dunnett’s correction.

Article Snippet: Mouse anti-GAK antibody (Santa Cruz Biotechnology, catalog: sc-137066); rabbit anti-GAK antibody (Invitrogen, Thermo Fisher Scientific, catalog: PA5-15321); mouse anti–transducin-like enhancer of split 4 (TLE4) antibody (Santa Cruz Biotechnology, catalog: sc-365406); rabbit anti-IκBα (Santa Cruz Biotechnology, catalog: sc-371); rabbit anti–NF-κB p65 (Cell Signaling Technology, catalog: 8242); rabbit anti-GADD45B antibody (Abcam, catalog: ab105060); rabbit anti–phospho-NF-κB p65 (Ser536) (Cell Signaling Technology, catalog: 3033); rabbit anti-WT1 antibody (Abcam, catalog: ab89901); mouse anti-WT1 antibody (MilliporeSigma, catalog: 05-753); rabbit anti-CAPNS1 antibody (MilliporeSigma, catalog: HPA006872); guinea pig anti-nephrin antibody (Progen, catalog: GP-N2); mouse anti-talin1 antibody (Cancer Research Technology, clone: 97H6); rabbit anti–β-actin antibody (Cell Signaling Technology, catalog: 5174); Alexa Fluor 488–conjugated phalloidin (Invitrogen, Thermo Fisher Scientific, catalog: A12379); Alexa Fluor 594–conjugated phalloidin (Invitrogen, Thermo Fisher Scientific, catalog: A12381); Alexa Fluor 488–conjugated goat anti–mouse IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11001); Alexa Fluor 594–conjugated goat anti–rabbit IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11037); Alexa Fluor 594–conjugated goat anti–guinea pig IgG antibody (Invitrogen, Thermo Fisher Scientific, catalog: A-11076); DAPI/antifade solution (MilliporeSigma, catalog: S7113); mouse anti–mouse IgG horseradish peroxidase–conjugated (HRP-conjugated) antibody (Rockland, catalog: 18-8817-31); and rabbit anti–mouse IgG HRP-conjugated antibody (MilliporeSigma, catalog: AP160P) were purchased commercially.

Techniques: Western Blot, Control, Wilms Tumor Assay, Immunofluorescence, Expressing, Staining, Isolation